Navigation Links
MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
Date:10/4/2007

irology Laboratory, Universidad Catolica de Chile,

-- Friday, October 5, 2007; 12:30 - 2:00 p.m. in Poster Halls G-H.

-- This study assessed the safety and immunogenicity of

motavizumab, an investigational anti-RSV MAb, in young children

with a history of prematurity who received two sequential

seasons of the antibody.

RSV Surveillance: Retrospective and Current Data on the Variance in Season Onsets and Offsets (Poster Presentation #719) - Jessie R. Groothuis M.D., MedImmune,

-- Saturday, October 6, 2007; 12:15 - 1:45 p.m. in Poster Halls G-H.

-- A nationwide active surveillance program was established to

evaluate the variability of the RSV season temporally and

geographically in the United States. Laboratory results from a

three-year period were analyzed by month and by geographic

region.

Additional information regarding the IDSA 45TH Annual Meeting can be found at http://www.idsociety.org/Meetingshome.aspx?id=238 .

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis(R) (palivizumab), which was the first MAb to receive U.S. Food and Drug Administration (FDA) approval for an infectious disease. With the development of motavizumab, MedImmune continues to reinforce its commitment to developing anti-RSV products. In a head-to-head comparative Phase 3 trial with Synagis, motavizumab met its primary endpoint of reducing RSV-related hospitalizations in high-risk pe
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
(Date:12/17/2014)... MILAN , December 17, 2014 ... becoming nothing less than a hub of information concerning the ... A further addition to the recently launched ... world and has now been enriched by a new chapter ... A richly detailed and panoramic hub on ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... patients at Beaumont,Hospitals are the first in the world ... that is painless, faster, more accurate and precise,than other ... the new,technology, Omnibeam(R). The $3.3-million machine is manufactured in,England ... patient,was treated on Sept. 10. The painless treatment ...
... Pharmaceuticals,Inc. (Amex: KAL; FWB: CA4), a developer of ... gastrointestinal disorders and diseases, announced today,that complete enrollment ... to,treat low to intermediate grade neuroendocrine carcinoma (advanced,carcinoid ... designed,to enroll 40 patients, presently has patients enrolled ...
Cached Medicine Technology:Beaumont Patients 1st to get Next Generation of Radiation Treatment 2Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer 2Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer 3Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer 4
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... with the healthcare sector have benefited the Massage ... Given the discretionary characteristics of industry products, the anticipated ... the five-year period has provided consumers with the means ... adults that have received a massage in a given ...
(Date:12/20/2014)... The print component of Healthy Aging is distributed within ... copies and an estimated readership of 420,000. The digital ... strategy and across a network of top news sites ... the campaign, click here . , The publication ... CTV’s The Social. Lainey Lui, Melissa Grelo, Traci ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
(Date:12/20/2014)... December 20, 2014 Developers of ... of a new plugin for Final Cut Pro X ... “TranSlice Volume 5 allows users to create hand drawn ... Said Christina Austin, CEO of Pixel Film Studios. “TranSlice ... professionalism while maintaining an easy to use interface.” , ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... of Innovation in ... Provider, SILVER SPRING, Md. and CAMBRIDGE, Mass., ... for Medical Simulation (CMS) today,announced that they are ... facility,s already cutting edge simulation programs.,B-Line Medical will ...
... Inc.,(Nasdaq: CYNO ), a leading developer and ... systems, today announced that the company,will present at ... New York,City. Chief Financial Officer Timothy Baker ... financial results in a presentation,beginning at 1:30 p.m. ...
... DEL MAR, Calif., Sept. 10 "Portuguese speaking,Brazil ... surgery," claims Dr.,Barry L. Friedberg. In recognition of ... book, is now scheduled for,a Portuguese translation after ... University Press. Knowledge acquired in this book will,empower ...
... marketing campaign celebrates Freedom to Breathe Act, ... of a,new marketing campaign designed to educate and ... statewide smoke-free law that goes into effect,on October ... workplaces smoke-free,including bars, restaurants and private clubs. Called ...
... healthy women, breast cancer survivors reported more days of ... in the October 15, 2007 issue of CANCER, a ... who received both chemotherapy and radiotherapy reported the most ... complaint in the general population and, anecdotally, common among ...
... be deadly for skiers, mountain climbers, regardless of fitness , ... high altitude pulmonary edema (HAPE) -- a life-threatening buildup of ... -- has been launched at the University of Edinburgh in ... at altitudes as low as 2,500 meters and can affect ...
Cached Medicine News:Health News:B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership 2Health News:B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership 3Health News:Cynosure to Present at the Maxim Group Growth Conference 2Health News:Cosmetic Surgery & Exotic Brazil 2Health News:Fresh Air Campaign to Showcase Minnesotans' Love of Smoke-Free Air 2Health News:Chemotherapy may be culprit for fatigue in breast cancer survivors 2
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: